Finance

Lists
WHWK:NASDAQ
Whitehawk Therapeutics Inc
$3.52
+1.44%
(+0.050) 1D
$3.45
-1.99% (-0.070)
After hours
Closed: Oct 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WHWK...
Open
$3.47
High
$3.54
Low
$3.40
Mkt. cap
200.67M
Avg. vol.
334.93K
Volume
320.26K
52-wk high
$5.50
52-wk low
$1.87
EPS
-$3.03
Beta
0.92
Shares outstanding
57.01M
No. of employees
32
Open
$3.47
High
$3.54
Low
$3.40
Mkt. cap
200.67M
Avg. vol.
334.93K
Volume
320.26K
52-wk high
$5.50
52-wk low
$1.87
EPS
-$3.03
Beta
0.92
Shares outstanding
57.01M
No. of employees
32
News stories
From web sources and news partners
About Whitehawk Therapeutics Inc
CEO-
Employees32
Founded2007
Headquarters-
SectorBiotechnology
Websiteir.whitehawktx.com
Analyst ratings
Based on 5 analysts giving stock ratings to WHWK in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for WHWK in the last 3 months.
Highest
Current $3.52
$9.00 (+155.68%)
Average
$8.00 (+127.27%)
Lowest
$7.00 (+98.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Dara Azar
Stifel Nicolaus
Buy
Initiated
$9.00
+155.7%
10/01/2026
Boris Peaker
JonesTrading
Buy
Maintained
$7.00
+98.9%
09/14/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$7.00
+98.9%
08/07/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/06/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
$9.00
+155.7%
07/13/2026
Yuan Zhi
B. Riley Securities
Buy
Initiated
$10.00
+184.1%
06/25/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$7.00
+98.9%
05/08/2026
Robert Burns
H.C. Wainwright
Hold
Reiterated
-
-
04/21/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$8.00
+127.3%
04/16/2026
Soumit Roy
JonesTrading
Buy
Maintained
$7.00
+98.9%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
14.34M
-71.94M
-
-
Cost of revenue
14.34M
-71.94M
-
-
Research and development expenses
-
90.96M
17.23M
12.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.20M
5.87M
6.29M
5.22M
Operating expense
5.20M
96.83M
23.52M
18.11M
Total operating expenses
19.55M
24.89M
23.52M
18.11M
Operating income
-19.55M
-24.89M
-23.52M
-18.11M
Other non operating income
127.00K
17.00K
-
-
EBT including unusual items
-17.75M
-23.25M
-22.19M
-16.64M
EBT excluding unusual items
-17.57M
-23.25M
-22.19M
-16.64M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.75M
-23.25M
-22.19M
-16.64M
Net profit margin
-
-
-
-
Earnings per share
-0.25
-0.34
-0.32
-0.20
Interest and investment income
1.85M
1.61M
1.33M
1.48M
Interest expense
-
-
-
-
Net interest expenses
1.85M
1.61M
1.33M
1.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.54M
-24.89M
-23.52M
-18.11M
Gain or loss from assets sale
177.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps